The Head Offices of Seattle Genetics are located at Bothell’s Cascade Business Park. The building does not show any sign of science until you enter the lobby where there is a triangular sculpture which is green in color and it is likely to win the organization a performer cred. The sculpture is made of a simplified human antibody and is made of Lego bricks. Seattle Genetics was established in 1998, and the pharmaceutical firm has mainly been dealing with the study, influence as well as the packaging of drugs. The Lego bricks are more than a sculpture as it defines the power of the company to alter their ability and associate it with a therapy.
Seattle Genetics has had the strategy of becoming a leader in the antibody development and also the distribution of drugs. Seattle Genetics has also gone through challenges which have troubled the pharmaceutical industry, it is determined not to end up like Immunex after it was acquired by Amgen. With the firm having about 900 staff and is valued at $10 billion, it is listed to be among the largest biotech companies in Washington. Seattle Genetics is richly investing in their marketing techniques as well as their research to reach the level of becoming the largest pharmaceutical firm. The organization has had plans of adding more employers into the company. One of the drugs the firm has developed is Adcetrics which they consider as their flagship. The drug is used to treat Hodgkin lymphoma. The firm is carrying out a study on the effect of the drugs and if the test will be positive it is estimated that the sales of the rugs will rise.
Clay Siegal is the co-founder of Seattle Genetics. He is also the President, the Chief Executive Officer, and the Chairman of the Board of Directors of Seattle Genetics. Mr. Clay Siegal is a scientist by profession and he has specialized in cancer therapy. When he established Seattle Genetics, he made sure that the firm is founded on exact research, invention, as well as drug improvement practice. Clay is passionate about helping cancer patients. Since the foundation of Seattle Genetics, Clay has been on the forefront of directing the firm into its afoot position of manufacturing Antibody-drug Conjugates (ADCs). He also led Seattle to acquire the 2011 FDA approval of its first ADC product, ADCETRICS. Mr. Siegal has also assisted Seattle to into multiple agreements with other pharmaceutical organizations including; AbbVie, Pfizer, and GlaxoSmithKline. Clay Siegal continues to help others through his scientific inventions.